Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and a cool breeze is wafting by. So we are ignoring the gloom by keeping busy. After all, there is much to be done. There are deadlines to meet, a variety of reading material to digest, and calls to make. We trust you can relate. So please join us as we fortify ourselves with more cups of stimulation — we are back to mountain blueberry — and get started. Hope you conquer the world and accomplish much. And of course, be in touch….
Bavarian Nordic is making more of a smallpox vaccine typically stockpiled in case of biological warfare, as governments seek doses that also offer protection against monkeypox amid an unusual outbreak around the world, The Wall Street Journal reports. Monkeypox has been reported in at least 17 countries, but there is no vaccine directed specifically against monkeypox. Smallpox vaccines like the Bavarian Nordic shot have been shown in studies to be effective at preventing monkeypox, which is closely related to smallpox but much less severe. And Moderna is testing potential vaccines against monkeypox in pre-clinical trials, Reuters adds.
The gold rush for drugmakers making Covid-19 vaccines and treatments might be over, as demand plateaus, supplies turn ample, and the pandemic evolves, The Wall Street Journal writes. Merck and Johnson & Johnson are among the companies cutting sales expectations for pandemic products this year as they assess the outlook. Analysts, meantime, are lowering sales estimates for Covid-19 drugs such as the Pfizer antiviral pill, Paxlovid, citing softening demand and few new supply deals. The situation marks a new phase in the pandemic. “This year is probably the peak, then going forward, it’s going to decline,” said Cantor Fitzgerald analyst Louise Chen. “The question is how much?”
Create a display name to comment
This name will appear with your comment